Compounded Tirzepatide: What It Is and Whether It's Legal in 2026

Compounded tirzepatide is a version of the drug made by a pharmacist or doctor who combines, mixes, or alters ingredients to create a medication, rather than by Eli Lilly, the manufacturer of the FDA-approved products Mounjaro and Zepbound ^[2]. It is not a generic, and it is not reviewed by the FDA for safety, effectiveness, or quality before it reaches patients ^[3][2].

As of 2026, mass compounding of tirzepatide is not legal. The window that allowed it closed when the FDA determined on December 19, 2024 that the tirzepatide shortage was resolved ^[2][6]. Enforcement discretion ended on February 18, 2025 for state-licensed pharmacies and physicians, or on the date of the district court’s ruling on the compounders’ injunction motion, March 5, 2025, whichever was longer, and on March 19, 2025 for outsourcing facilities ^[6]. A narrow exception remains for genuinely individualized prescriptions for identified patients, which is described below.

What is compounded tirzepatide, exactly?

Compounding is “a process by which a pharmacist or doctor combines, mixes, or alters ingredients to create a medication” ^[2]. Tirzepatide is a GLP-1 receptor agonist that helps manage blood sugar levels, and it is the active ingredient in two FDA-approved products ^[2].

Mounjaro was approved by the FDA in May 2022 to treat type 2 diabetes, and Zepbound was approved in November 2023 to treat obesity and other weight-related conditions ^[2][1]. Both were originally approved as pre-filled single-dose pens, with single-dose vials approved later ^[2]. Mounjaro and Zepbound are the only FDA-approved tirzepatide products ^[2][4].

Lilly states that it does not supply the tirzepatide active ingredient to compounding pharmacies, med-spas, wellness centers, online retailers, or other manufacturers, and that it does not know where compounders are obtaining the ingredient they sell ^[4]. Lilly’s exclusivity on the tirzepatide active moiety runs to 2027; federal law bars the FDA from approving another manufacturer’s application using the same active moiety for five years after initial approval ^[2].

Is compounded tirzepatide the same thing as a generic Zepbound?

No. Compounded drugs are not generics. They are essentially copies that were permitted to be made by compounding pharmacies during a drug shortage ^[7].

Compounded drugs are not FDA-approved, which means the FDA does not review them for safety, effectiveness, or quality before they are marketed ^[3][2]. They skip the “long, comprehensive, and costly testing process” that FDA-approved drugs go through ^[2].

The FDA’s position is that compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug ^[3][5], and that compounded drugs pose a higher risk to patients than FDA-approved drugs ^[5][4].

Why was compounded tirzepatide so easy to get in 2023 and 2024?

Federal law normally prohibits compounding drugs that are essentially copies of a commercially available drug or of FDA-approved drugs ^[2]. But that prohibition is temporarily suspended while the drug appears on the FDA’s drug shortage list ^[2][5].

The FDA added Mounjaro to its drug shortage list in December 2022 and Zepbound in April 2024 ^[2]. While a drug is on the shortage list, it is not considered “commercially available” for purposes of the copy restrictions that apply to state-licensed pharmacies ^[5]. That opened the door for compounders to make and sell tirzepatide copies.

Price drove demand. During the shortage, Zepbound carried a sticker price of more than $1,086.37 a month, while compounded tirzepatide sold for as little as $99 a month ^[7]. During the shortage period, Lilly spent approximately $23 billion to expand its manufacturing capacity, building, expanding, and acquiring facilities in the United States and Europe ^[2].

When did compounded tirzepatide become illegal, exactly?

The wind-down happened in stages:

Date	What happened
October 2, 2024	FDA posted an update determining the tirzepatide injection shortage was resolved [2][6]
December 19, 2024	FDA issued a Declaratory Order and Decision Memorandum reaffirming the shortage was resolved, finding supply would “meet or exceed projected demand” [2][6]
December 19, 2024	FDA announced 60 days of non-enforcement for 503A pharmacies and physicians, and 90 days for 503B outsourcing facilities, for an orderly transition [2][6]
February 18, 2025	Enforcement discretion ended for state-licensed pharmacies and physicians compounding under section 503A (or the date of the court’s preliminary injunction ruling, whichever was longer) [6]
March 5, 2025	District court denied the compounders’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (N.D. Tex.) [6][2]
March 19, 2025	FDA stated it did not intend to act against 503B outsourcing facilities until this date [6]

Between the October 2024 determination and the December 19, 2024 reaffirmation, the compounders filed suit, and the district court granted the FDA’s unopposed motion for a voluntary remand and a stay so the FDA could re-evaluate its October decision ^[2]. The cited opinion does not date that remand.

Pharmacies were allowed to sell stock already produced until it ran out or expired ^[7]. For outsourcing facilities, FDA policy provides flexibility to fill orders received while the drug was in shortage, but the agency may take action if a facility continues to fill new orders after the drug is removed from the shortage list, or if it fills existing orders more than 60 days after removal ^[5].

The semaglutide timeline came later: the FDA declared that shortage resolved on February 21, 2025, with the 503A enforcement period ending April 22, 2025 and the 503B period ending May 22, 2025 ^[6].

What happened when compounders sued the FDA?

The Outsourcing Facilities Association and North American Custom Laboratories, LLC, doing business as FarmaKeio Custom Compounding, sued the FDA. They argued that the FDA should have used notice-and-comment rulemaking under the Administrative Procedure Act, and that the shortage determination was arbitrary and capricious ^[2]. Eli Lilly intervened in the case ^[2].

The district court (N.D. Tex., USDC No. 4:24-CV-953) granted summary judgment for the FDA and Lilly ^[2][9]. The Fifth Circuit affirmed on August 27, 2026 in an unpublished per curiam opinion, No. 25-10600, issued by Judges Richman, Duncan, and Oldham ^[2][10].

The panel assumed, without deciding, that the FDA erred by not using notice-and-comment procedures, but found the compounders failed to show prejudice. The court also concluded the FDA’s shortage determination was not arbitrary or capricious ^[2]. The FDA had noted that multiple interested parties — including Lilly, individual patients, healthcare providers, compounders, associations, and telehealth companies — did in fact submit information both before the initial October 2024 determination and during the re-evaluation ^[2]. A companion case on semaglutide, Outsourcing Facilities Association v. FDA v. Novo Nordisk, was decided by the same panel in a separate opinion ^[2].

Is any compounding of tirzepatide still legal in 2026?

A narrow path remains, but it is not a license to mass-produce copies.

Under section 503A, a drug must be compounded for an individual patient based on a prescription, and the compounder may not compound essentially copies of a commercially available drug regularly or in inordinate amounts ^[6][5]. A compounded product is considered essentially a copy if it has the same active pharmaceutical ingredient as the commercially available product in the same, similar, or easily substitutable strength, and the commercial product can be used by the same route of administration ^[6].

The exception the FDA describes is narrow: a prescriber must determine and document that the compounded product contains a change that produces a significant difference from the commercially available product for an identified individual patient ^[6]. An example of legitimate custom compounding is a patient who is allergic to a preservative in the commercial product ^[7].

The FDA has also stated that, at this time, it does not intend to take action against a compounder for essentially-copy compounding if the compounder fills four or fewer prescriptions of that product during a calendar month ^[6]. That is an enforcement position, not a legal entitlement to compound copies.

For 503B outsourcing facilities, the rules are stricter. A bulk drug substance must appear on the 503B bulks list, or the drug compounded from it must be on the FDA’s drug shortage list at the time of compounding, distribution, and dispensing ^[6]. As of the FDA’s April 1, 2026 statement, tirzepatide and semaglutide appear on neither the 503B bulks list nor the shortage list ^[6]. The FDA has also proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list ^[12], and a Federal Register notice published June 26, 2026 extended the comment period on the 503B clinical-need bulks list ^[13].

Enforcement is active. The FDA issued a warning letter to ProRx LLC dated April 7, 2026 ^[11], and a warning letter has reported sterility failures and subpotent GLP-1 compounded drugs at a compounding pharmacy ^[20]. On September 18, 2026, the FDA sent Empower Clinic Services, which does business as Empower Pharmacy, a warning letter for compounding drug products that failed to meet the conditions of section 503A, including essentially copies of FDA-approved semaglutide and tirzepatide products compounded regularly and in inordinate amounts ^[22][23]. The letter followed a November 2025 inspection of the firm’s Houston facility that found sterile products were prepared, packed, or held under insanitary conditions, which could result in products becoming contaminated with filth or rendered injurious to health, and it noted that some orders lacked a prescriber determination of a significant difference from the commercially available product while other purported determinations appeared to be repeated verbatim across many records, suggesting they may have been pre-generated ^[22][23]. Empower’s response to the insanitary-conditions concerns, communicated in a Form 483 at the end of the inspection, failed to satisfy the agency, which gave the firm 15 working days to respond in writing detailing the specific steps taken; as of September 24, 2026, Empower continued to list tirzepatide and semaglutide products for sale on its website ^[22][23].

Does adding vitamin B12 or niacinamide make compounded tirzepatide legal?

The FDA has addressed the additive question directly, using semaglutide as its example. The agency has said that a compounded product that combines semaglutide API with another API, such as vitamin B12 (cyanocobalamin), may still be essentially a copy of a commercially available drug product. The two-drug copy test applies when the compounded product contains the same APIs as two or more commercially available products in the same, similar, or easily substitutable strength, and the commercial products can be used by the same route of administration — unless there is documentation of a prescriber determination of a significant difference ^[6]. The FDA illustrates “same, similar or easily substitutable strength” as within 10% of the strengths of the respective commercially available products ^[6].

The niacinamide claim comes from Lilly, not the FDA. Lilly’s complaint against Mochi Health alleges the company switched patients to compounded tirzepatide with additives such as niacinamide, and to doses Lilly does not offer, at least five times in eight months ^[7]. Lilly sued the compounding pharmacies Strive and Empower on April 1, 2025, and the telehealth firms Mochi Health, Willow Health, Fella Health/Delilah, and Henry Meds on April 23, 2025 ^[7]. Lilly said in a statement that “anyone continuing to sell mass compounded tirzepatide is breaking the law and deceiving patients” ^[7].

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, an advocacy group for compounding pharmacies, told NPR there is no bright line between the corporate practice of medicine and legitimate prescriber-driven customization of a drug ^[7]. A study in JAMA Health Forum has examined the post-shortage compounded GLP-1 receptor agonist market in two states with potentially high demand ^[14].

Are oral, under-the-tongue, or nasal tirzepatide products approved?

No. The FDA has approved tirzepatide only for administration by under-the-skin injection ^[4]. No regulator has evaluated the safety or effectiveness of any oral or nasal form of “tirzepatide” ^[4][17].

Certain online pharmacies advertise compounded pill, under-the-tongue, and nasal spray versions ^[4]. Lilly’s complaints allege that Henry Meds and Fella Health sold tirzepatide in pill form, which has never been FDA-approved ^[7].

The Connecticut Attorney General sent a letter to weight-loss clinics and spas dated May 21, 2025 ^[18]. Separately, products labeled “research purposes only” or “not for human consumption” are not purified to pharmaceutical-grade levels and should not be injected ^[4].

What safety problems have been reported with compounded tirzepatide?

As of May 31, 2026, the FDA had received more than 730 adverse event reports associated with compounded tirzepatide, and 990 associated with compounded semaglutide ^[3]. Federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to the FDA, so underreporting is likely ^[3]. Many of the reported events appear consistent with those of the FDA-approved products ^[3].

Documented problems include:

• Fraudulent labels. Some compounded semaglutide and tirzepatide products list compounding pharmacies that do not exist, or name real pharmacies that did not make the product ^[3]. One adverse event report tied to a product labeled as compounded tirzepatide from a pharmacy that did not compound it included injection-site redness, swelling, pain, and a red lump ^[3].
• Dosing errors. The FDA has received multiple reports of adverse events, some requiring hospitalization, related to dosing errors with compounded injectable semaglutide — patients measuring and self-administering incorrect doses, and in some cases healthcare professionals miscalculating doses ^[3]. Separately, the agency has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide in doses beyond what is in the FDA-approved drug label ^[3].
• Multi-dose vials. The FDA recommends discarding vials containing multiple doses within 28 days of first use, and using a new sterile needle and syringe for each dose ^[3].
• Shipping problems. Compounded GLP-1s have arrived warm or with inadequate ice packs; the FDA recommends not using an injectable GLP-1 that arrives warm or without sufficient refrigeration ^[3].
• Border actions. The FDA has established import alert 66-80, a green list, to stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the U.S. supply chain ^[3].

Lilly has reported finding compounded drugs advertised as tirzepatide that contained bacteria, high impurity levels, pink coloring instead of colorless, a different chemical structure than its medicines, and in one case nothing more than sugar alcohol ^[4]. In March 2026, Lilly reported finding an impurity in a compounded version of its weight-loss drug and warned of health risks ^[16]. The Australian government announced a ban on compounded tirzepatide and similar compounded weight-loss medicines on May 21, 2024 ^[4].

Two related cautions from the FDA: retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any condition ^[3]. And on semaglutide specifically, the FDA is aware of no lawful basis for compounding the salt forms, such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the approved drug ^[3].

How much does brand-name Zepbound cost compared with compounded?

During the shortage, compounded tirzepatide sold for as little as $99 a month while Zepbound’s sticker price was more than $1,086.37 a month ^[7]. LillyDirect currently lists self-pay program prices for Zepbound, and these are program prices, not list prices: eligibility is required, savings are subject to monthly and annual limits, the program is not insurance, and Lilly may amend or terminate it at any time ^[1].

Zepbound dose (KwikPen or single-dose vial)	LillyDirect self-pay price	Regular price if not refilled within 45 days
2.5 mg (starting dose, not approved as a maintenance dose)	Starting at $299/month	—
5 mg	Starting at $399/month	—
7.5 mg	Starting at $449/month with the Zepbound Journey Program	$499
10 mg	Starting at $449/month with the Zepbound Journey Program	$699
12.5 mg	Starting at $449/month with the Zepbound Journey Program	$699
15 mg	Starting at $449/month with the Zepbound Journey Program	$699

A “month” is defined as 28 days and one single-patient-use KwikPen, or 28 days and four single-dose vials ^[1]. Pen needles for the KwikPen, or a needle and syringe for the vial, must be purchased separately; the Single-Dose Pen includes a needle ^[1]. With insurance, the Single-Dose Pen is listed as low as $25 per month for up to a 3-month prescription ^[1]. HSA/FSA eligibility may vary by plan, and LillyDirect offers free delivery and pickup options ^[1]. A Medicare GLP-1 Bridge program is referenced for eligible Medicare Part D patients with a Zepbound KwikPen prescription for weight management ^[1].

What red flags should you watch for before paying?

The FDA lists these telehealth warning signs ^[3]:

• Claims that the compounded drug is the same as an FDA-approved drug
• Deep discounts or prices that seem too good to be true
• Medicine that looks different from what you have received before, or arrives in broken or damaged packaging, or lacks instructions for use
• No screening or prescription by a licensed doctor before providing medicine
• No licensed doctor available to answer questions after you receive the medication
• Spelling errors on the label or an incorrect pharmacy address
• A pharmacy name on the label that may be fraudulent

The FDA advises patients to obtain a prescription from their doctor and fill it at a state-licensed pharmacy, and points to its BeSafeRx campaign for buying prescription medicines online safely ^[3]. Questions about a label or instructions for use should go to the compounder or the telehealth platform where the drug was purchased ^[3]. The FDA maintains a page listing compounding inspections, recalls, and other actions ^[21].

Lilly adds that anything sold simply as “tirzepatide,” rather than Mounjaro or Zepbound, was not made by, studied by, or sold by Lilly and is not FDA-approved, and that Lilly never sells Mounjaro or Zepbound on social media ^[4].

What if you’re currently taking compounded tirzepatide?

Do not stop or change medication on your own. The FDA encourages patients to talk with their healthcare provider about their medicines and about how to measure and administer the intended dose ^[3]. The agency has also said providers should be vigilant when prescribing compounded semaglutide or tirzepatide and when setting doses and titration schedules ^[3].

Incretin medicines, including Mounjaro and Zepbound, require a prescription and must be used under the supervision of a healthcare provider ^[4]. Problems can be reported to the FDA through the adverse event reporting channels referenced on its GLP-1 concerns page ^[3].

Sources

1. Eli Lilly and Company. Zepbound (tirzepatide) shipped to you through LillyDirect.
2. US Court of Appeals for the Fifth Circuit. Outsourcing Facilities Association v. FDA, No. 25-10600. August 27, 2026.
3. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
4. Eli Lilly and Company. An open letter from Eli Lilly and Company regarding certain practices related to Mounjaro and Zepbound. June 20, 2024.
5. US Food and Drug Administration. Compounding when drugs are on FDA’s drug shortages list.
6. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
7. NPR. Eli Lilly sues companies selling alternative versions of its weight loss drug. April 23, 2025.
8. Becker’s Hospital Review. Court sides with FDA in tirzepatide shortage fight: 5 notes. September 2, 2026.
9. STAT. Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list. May 7, 2025.
10. Clark Hill. Fifth Circuit upholds FDA GLP-1 shortage decisions, narrowing path for mass-market compounding. September 10, 2026.
11. US Food and Drug Administration. Warning letter: ProRx LLC. April 7, 2026.
12. US Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list.
13. Federal Register. List of bulk drug substances for which there is a clinical need under section 503B; extension of comment period. June 26, 2026.
14. JAMA Health Forum. Postshortage compounded GLP-1 RA market in 2 states with potentially high demand.
15. Medscape. Compounded GLP-1s still widespread despite shortage fix. July 20, 2026.
16. Reuters. Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks. March 12, 2026.
17. Eli Lilly and Company. What are the health risks of using compounded tirzepatide?
18. Connecticut Office of the Attorney General. Letter to weight loss clinics and med spas regarding compounded GLP-1 medications. May 21, 2025.
19. Becker’s Hospital Review. FDA warns on compounded GLP-1s amid 1,700+ safety reports. September 8, 2026.
20. The FDA Group Insider. FDA warning letter breakdown: sterility failures, subpotent GLP-1 drugs, and a compounding pharmacy operating without control.
21. US Food and Drug Administration. Compounding: inspections, recalls, and other actions.
22. US Food and Drug Administration. Warning letter: Empower Clinic Services, LLC dba Empower Pharmacy. September 18, 2026.
23. BioSpace. FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’.